While BLU-285 demonstrated strong activity against clinically relevant single mutations in either the activation loop or the ATP-binding pocket of KIT and PDGFRA, tumor sensitivity was increased in the setting of dual mutants of the juxtamembrane and ATP-binding pocket and protein regions (e.g. exon 11/exon 17). This evidence concerns the gene PDGFRA and neoplasm.